<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: items could", fill: "#c08081"},
{source: "1: items could", target: "1: Companys ", fill: "#c08081"},
{source: "1: Companys ", target: "1: differ from", fill: "#c08081"},
{source: "1: items could", target: "2: Such ", fill: "#343434"},
{source: "2: Such ", target: "2: factors among others may", fill: "#343434"},
{source: "2: factors among others may", target: "2: Companys ", fill: "#343434"},
{source: "2: Companys ", target: "2: operations", fill: "#343434"},
{source: "2: Such ", target: "4: The Company ", fill: "#0d98ba"},
{source: "4: The Company ", target: "4: competitive environment", fill: "#0d98ba"},
{source: "4: The Company ", target: "10: Because ", fill: "#48d1cc"},
{source: "10: Because ", target: "10: factors past financial", fill: "#48d1cc"},
{source: "10: factors past financial", target: "10: performance should", fill: "#48d1cc"},
{source: "10: performance should", target: "10: indication", fill: "#48d1cc"},
{source: "10: indication", target: "10: future performance", fill: "#48d1cc"},
{source: "10: Because ", target: "32: the Companys ", fill: "#21abcd"},
{source: "32: the Companys ", target: "32: financial condition", fill: "#21abcd"},
{source: "32: financial condition", target: "32: operations", fill: "#21abcd"},
{source: "32: the Companys ", target: "33: approval manufacturing", fill: "#f94d00"},
{source: "33: approval manufacturing", target: "33: Companys ", fill: "#f94d00"},
{source: "33: Companys ", target: "33: US Significant ", fill: "#f94d00"},
{source: "33: US Significant ", target: "33: government regulation", fill: "#f94d00"},
{source: "33: government regulation", target: "33: Canada Japan Europe ", fill: "#f94d00"},
{source: "33: approval manufacturing", target: "34: manufacturer", fill: "#c32148"},
{source: "34: manufacturer", target: "34: register with", fill: "#c32148"},
{source: "34: register with", target: "34: the FDA ", fill: "#c32148"},
{source: "34: the FDA ", target: "34: compliance with", fill: "#c32148"},
{source: "34: compliance with", target: "34: FDAs Quality System Regulation QSR ", fill: "#c32148"},
{source: "34: FDAs Quality System Regulation QSR ", target: "34: requirements", fill: "#c32148"},
{source: "34: requirements", target: "34: manufacturers", fill: "#c32148"},
{source: "34: manufacturers", target: "34: medical devices", fill: "#c32148"},
{source: "34: medical devices", target: "34: regulations", fill: "#c32148"},
{source: "34: regulations", target: "34: documentation", fill: "#c32148"},
{source: "34: manufacturer", target: "43: pricing sales", fill: "#6d9bc3"},
{source: "43: pricing sales", target: "43: marketing programs", fill: "#6d9bc3"},
{source: "43: marketing programs", target: "43: arrangements", fill: "#6d9bc3"},
{source: "43: arrangements", target: "43: under increasing scrutiny from", fill: "#6d9bc3"},
{source: "43: under increasing scrutiny from", target: "43: regulatory", fill: "#6d9bc3"},
{source: "43: regulatory", target: "43: investigative", fill: "#6d9bc3"},
{source: "43: investigative", target: "43: prosecutorial", fill: "#6d9bc3"},
{source: "43: prosecutorial", target: "43: administrative entities", fill: "#6d9bc3"},
{source: "43: pricing sales", target: "46: government", fill: "#e08d3c"},
{source: "46: government", target: "46: them could institute civil", fill: "#e08d3c"},
{source: "46: them could institute civil", target: "46: criminal proceedings", fill: "#e08d3c"},
{source: "46: criminal proceedings", target: "46: resolved unfavorably could", fill: "#e08d3c"},
{source: "46: resolved unfavorably could", target: "46: any of Company ", fill: "#e08d3c"},
{source: "46: any of Company ", target: "46: administrative", fill: "#e08d3c"},
{source: "46: administrative", target: "46: reimbursement", fill: "#e08d3c"},
{source: "46: government", target: "53: reimbursement", fill: "#f0f"},
{source: "53: reimbursement", target: "53: significantly", fill: "#f0f"},
{source: "53: significantly", target: "53: countrytocountry", fill: "#f0f"},
{source: "53: reimbursement", target: "66: Sales of the Companys ", fill: "#e4717a"},
{source: "66: Sales of the Companys ", target: "66: sleep apnea products accounted", fill: "#e4717a"},
{source: "66: sleep apnea products accounted", target: "66: Companys ", fill: "#e4717a"},
{source: "66: Sales of the Companys ", target: "69: depends on", fill: "#ffe135"},
{source: "69: depends on", target: "69: effectively market", fill: "#ffe135"},
{source: "69: effectively market", target: "69: home healthcare providers", fill: "#ffe135"},
{source: "69: home healthcare providers", target: "69: sleep laboratories", fill: "#ffe135"},
{source: "69: depends on", target: "70: The Company ", fill: "#cfb53b"},
{source: "70: The Company ", target: "70: markets certain products primarily", fill: "#cfb53b"},
{source: "70: markets certain products primarily", target: "70: homecare providers", fill: "#cfb53b"},
{source: "70: homecare providers", target: "70: sleep clinics", fill: "#cfb53b"},
{source: "70: sleep clinics", target: "70: sleep disorders", fill: "#cfb53b"},
{source: "70: The Company ", target: "79: inability", fill: "#00703c"},
{source: "79: inability", target: "79: support continued growth could negatively impact", fill: "#00703c"},
{source: "79: inability", target: "START_HERE", fill: "#00703c"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Department Stores</td>
    </tr>
    <tr>
      <td>Oil and Gas Refining and Marketing and Transportation</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Companys,_procés_a_Catalunya">Companys, procés a Catalunya</a></td>
      <td>Companys, procés a Catalunya (Spanish: Companys, proceso a Cataluña) is a 1979 Spanish Catalan drama film directed by Josep Maria Forn, based on the last months of the life of the President of Catalonia, Lluís Companys, in which he shows his detention by the Nazis and his subsequent execution by the Spanish Francoists. It competed in the Un Certain Regard section at the 1979 Cannes Film Festival.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Conxita_Julià">Conxita Julià</a></td>
      <td>Conxita Julià i Farrés (Catalan pronunciation: [kuɲˈʃitə ʒuliˈa j fəˈres]; 11 June 1920 – 9 January 2019), also known as Conxita de Carrasco, was a Catalan woman noted for her dealings with Lluís Companys, President of Catalonia, in the 1930s, and for her poetry. Julià died in January 2019 at the age of 98.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Amazon_(company)">Amazon (company)</a></td>
      <td>Amazon.com, Inc. ( AM-ə-zon) is an American multinational technology company which focuses on e-commerce, cloud computing, digital streaming, and artificial intelligence.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/El_Tarròs">El Tarròs</a></td>
      <td>El Tarròs (Spanish: Tarrós) is a small village in Tornabous municipality, in the province of Lleida, in Catalonia, Spain. In 2008 it had 100 inhabitants.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Pokémon_Company">The Pokémon Company</a></td>
      <td>The Pokémon Company (株式会社ポケモン, Kabushiki gaisha Pokémon) is a Japanese company responsible for brand management, production, publishing, marketing and licensing of the Pokémon franchise, which consists of video game software, a trading card game, anime television series, films, manga, home entertainment products, merchandise, and other ventures. It was established through a joint investment by the three businesses holding the copyright of Pokémon: Nintendo, Game Freak, and Creatures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Weather_Company">The Weather Company</a></td>
      <td>The Weather Company is a weather forecasting and information technology company that owns and operates weather.com and Weather Underground. The Weather Company has been a subsidiary of the Watson &amp; Cloud Platform business unit of IBM since 2016.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_analysis">Financial analysis</a></td>
      <td>Financial analysis (also referred to as financial statement analysis or accounting analysis or Analysis of finance) refers to an assessment of the viability, stability, and profitability of a business, sub-business or project. \nIt is performed by professionals who prepare reports using ratios and other techniques, that make use of information taken from financial statements and other reports.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_law">Financial law</a></td>
      <td>Financial law is the law and regulation of the insurance, derivatives, commercial banking, capital markets and investment management sectors. Understanding Financial law is crucial to appreciating the creation and formation of banking and financial regulation, as well as the legal framework for finance generally.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Trustmark_(bank)">Trustmark (bank)</a></td>
      <td>Trustmark is a commercial bank and financial services company headquartered in Jackson, Mississippi, United States, with subsidiaries Trustmark National Bank, Trustmark Investment Advisors, and Fisher Brown Bottrell Insurance. The bank's initial predecessor, The Jackson Bank, was chartered by the State of Mississippi in 1889.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_affairs">Regulatory affairs</a></td>
      <td>Regulatory affairs (RA), also called government affairs, is a profession within regulated industries, such as pharmaceuticals, medical devices, cosmetics, agrochemicals (plant protection products and fertilizers), energy, banking, telecom etc.  Regulatory affairs also has a very specific meaning within the healthcare industries (pharmaceuticals, medical devices, biologics and functional foods).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_A">Regulation A</a></td>
      <td>In the United States under the Securities Act of 1933, any offer to sell securities must either be registered with the United States Securities and Exchange Commission (SEC) or meet certain qualifications to exempt it from such registration. Regulation A (or Reg A) contains rules providing exemptions from the registration requirements, allowing some companies to use equity crowdfunding to offer and sell their securities without having to register the securities with the SEC. Regulation A offerings are intended to make access to capital possible for small and medium-sized companies that could not otherwise bear the costs of a normal SEC registration and to allow nonaccredited investors to participate in the offering.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Formula_One_regulations">Formula One regulations</a></td>
      <td>The numerous Formula One regulations, made and enforced by the FIA and later the FISA, have changed dramatically since the first Formula One World Championship in 1950. This article covers the current state of F1 technical and sporting regulations, as well as the history of the technical regulations since 1950.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_T_cell">Regulatory T cell</a></td>
      <td>The regulatory T cells (Tregs  or Treg cells), formerly known as suppressor T cells, are a subpopulation of T cells that modulate the immune system, maintain tolerance to self-antigens, and prevent autoimmune disease. Treg cells are immunosuppressive and generally suppress or downregulate induction and proliferation of effector T cells.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_law">Regulatory law</a></td>
      <td>Regulatory law refers to secondary legislation, including regulations, promulgated by an executive branch agency under a delegation from a legislature. It contrasts with statutory law promulgated by the legislative branch, and common law or case law promulgated by the judicial branch.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Diagnosis-related_group">Diagnosis-related group</a></td>
      <td>Diagnosis-related group (DRG) is a system to classify hospital cases into one of originally 467 groups, with the last group (coded as 470 through v24, 999 thereafter) being "Ungroupable". This system of classification was developed as a collaborative project by Robert B Fetter, PhD, of the Yale School of Management, and John D. Thompson, MPH, of the Yale School of Public Health.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_Others">Significant Others</a></td>
      <td>The term significant other (SO) has different uses in psychology and in colloquial language. Colloquially "significant other" is used as a gender-neutral term for a person's partner in an intimate relationship without disclosing or presuming anything about marital status, relationship status, gender identity, or sexual orientation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_form">Significant form</a></td>
      <td>Significant form refers to an aesthetic theory developed by English art critic Clive Bell which specified a set of criteria for what qualified as a work of art.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bit_numbering">Bit numbering</a></td>
      <td>In computing, bit numbering is the convention used to identify the bit positions in a binary number.\n\n\n== Bit significance and indexing ==\n\nIn computing, the least significant bit (LSB) is the bit position in a binary integer representing the binary 1s place of the integer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Internet">Internet</a></td>
      <td>In finance and economics, interest is payment from a borrower or deposit-taking financial institution to a lender or depositor of an amount above repayment of the principal sum (that is, the amount borrowed), at a particular rate. It is distinct from a fee which the borrower may pay the lender or some third party.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sleep">Sleep</a></td>
      <td>Sleep is a naturally recurring state of mind and body, characterized by altered consciousness, relatively inhibited sensory activity, reduced muscle activity and inhibition of nearly all voluntary muscles during rapid eye movement (REM) sleep, and reduced interactions with surroundings. It is distinguished from wakefulness by a decreased ability to react to stimuli, but more reactive than a coma or disorders of consciousness, with sleep displaying different, active brain patterns.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Market_economy">Market economy</a></td>
      <td>A market economy is an economic system in which the decisions regarding investment, production and distribution to the consumers are guided by the price signals created by the forces of supply and demand, where all suppliers and consumers are unimpeded by price controls or restrictions on contract freedom. The major characteristic of a market economy is the existence of factor markets that play a dominant role in the allocation of capital and the factors of production.Market economies range from minimally regulated free-market and laissez-faire systems where state activity is restricted to providing public goods and services and safeguarding private ownership, to interventionist forms where the government plays an active role in serving special interests and promoting social welfare.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Market_Garden">Operation Market Garden</a></td>
      <td>Operation Market Garden was an Allied military operation during the Second World War fought in the Netherlands from 17 to 25 September 1944. Its objective was to create a 64 mi (103 km) salient into German territory with a bridgehead over the River Rhine, creating an Allied invasion route into northern Germany.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Dassault_Falcon_20">Dassault Falcon 20</a></td>
      <td>The Dassault Falcon 20 is a French business jet developed and manufactured by Dassault Aviation. The first business jet developed by the firm, it became the first of a family of business jets to be produced under the same name; of these, both the smaller Falcon 10 and the larger trijet Falcon 50 were direct derivatives of the Falcon 20.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Royal_Cornwall_Hospitals_NHS_Trust">Royal Cornwall Hospitals NHS Trust</a></td>
      <td>The Royal Cornwall Hospitals NHS Trust is an NHS trust which runs West Cornwall Hospital, St Michael's Hospital, Royal Cornwall Hospital, and St Austell Hospital - Penrice Birthing Unit, in Cornwall, England.\n\n\n== History ==\nThe trust was established as the Royal Cornwall Hospitals and West Cornwall Hospital NHS Trust on 1 November 1991, and became operational on 1 April 1992.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Right_at_Home">Right at Home</a></td>
      <td>Right at Home In Home Care and Assistance is an international franchise system providing in-home care through independent, locally owned and operated Right at Home franchisee offices.  Based in Omaha, Nebraska, it focuses on caring for the elderly and those with Dementia, Alzheimer's Disease, Parkinson's Disease, and hospital recovery.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Home_Instead_Senior_Care_UK">Home Instead Senior Care UK</a></td>
      <td>Home Instead Senior Care UK is a network of franchises specialising relationship-led domiciliary care for the elderly, in support of aging in place. It is a franchise of Home Instead Senior Care based in Nebraska, founded in 1994, which was acquired by Honor Technology, based in San Francisco, in August 2021.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/National_Healthcare">National Healthcare</a></td>
      <td>National HealthCare Corporation is an American healthcare services provider. The company was founded in 1971 and is based in Murfreesboro, Tennessee.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Anosmia">Anosmia</a></td>
      <td>Anosmia, also known as smell blindness, is the loss of the ability to detect one or more smells. Anosmia may be temporary or permanent.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Ageusia">Ageusia</a></td>
      <td>Ageusia (from negative prefix a- and Ancient Greek γεῦσις geûsis 'taste') is the loss of taste functions of the tongue, particularly the inability to detect sweetness, sourness, bitterness, saltiness, and umami (meaning 'pleasant/savory taste'). It is sometimes confused with anosmia – a loss of the sense of smell.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>RESPIRONICS INC      Item 1A Risk Factors        The following factors, among other items, could cause the Company’s future     results to <font color="blue">differ from</font> those contained in forward-looking statements made in     this report and presented elsewhere by <font color="blue">management</font> from time-to-time</td>
    </tr>
    <tr>
      <td><font color="blue">Such     </font>factors, among others, may have a material adverse effect on the Company’s     business,  financial  condition  and  results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>operates in a     dynamic and <font color="blue">competitive environment</font></td>
    </tr>
    <tr>
      <td>New <font color="blue"><font color="blue">risk factors</font> affecting</font> the <font color="blue"><font color="blue">Company  </font>   </font>emerge from time-to-time and it is not possible for <font color="blue">management</font> to predict     all <font color="blue">such <font color="blue">risk factors</font></font></td>
    </tr>
    <tr>
      <td>Further, it is not possible to assess the impact of     all <font color="blue"><font color="blue">risk factors</font> on</font> <font color="blue">the Company </font>or the extent to which any individual factor     or <font color="blue">combination</font> of <font color="blue">factors may</font> cause actual results to <font color="blue">differ materially from</font>     those contained in any forward-looking statements</td>
    </tr>
    <tr>
      <td>Due to these inherent     risks  and <font color="blue">uncertainties</font>, investors should not place undue reliance on     forward-looking statements as a prediction of actual results</td>
    </tr>
    <tr>
      <td>Additionally,     the  Company undertakes <font color="blue">no obligation</font> to <font color="blue">publicly update</font> or revise any     forward-looking statements, whether as a result of new information, future     events or otherwise</td>
    </tr>
    <tr>
      <td>The following discussion of the Company’s <font color="blue">risk factors</font>     speaks only as of the <font color="blue">date on which</font> they were made and should be read in     <font color="blue">conjunction with</font> the <font color="blue">consolidated financial statements</font> and related notes     included  herein</td>
    </tr>
    <tr>
      <td><font color="blue">Because  </font>of these and other factors, past financial     <font color="blue">performance should</font> not be considered an <font color="blue">indication</font> of <font color="blue">future performance</font></td>
    </tr>
    <tr>
      <td>INDUSTRY RISKS        <font color="blue">The Company </font><font color="blue">participates</font> in a highly <font color="blue">competitive environment</font></td>
    </tr>
    <tr>
      <td>The markets <font color="blue">the Company </font><font color="blue">participates</font> in are <font color="blue">highly competitive</font> and are     <font color="blue">characterized by frequent product improvements</font> and <font color="blue">evolving <font color="blue">technology</font></font></td>
    </tr>
    <tr>
      <td>The     Company’s ability to <font color="blue">compete successfully depends</font>, in part, on its ability     to develop, <font color="blue">manufacture</font> and <font color="blue">market innovative new products</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font>     of <font color="blue">innovative new products by competitors</font> or the <font color="blue">discovery</font> of <font color="blue">alternative</font>     <font color="blue">treatments</font> or <font color="blue">potential cures</font> for the <font color="blue">conditions</font> that the Company’s products     <font color="blue">treat could</font> make Respironics’ <font color="blue">products noncompetitive</font> or obsolete</td>
    </tr>
    <tr>
      <td>Additionally, some <font color="blue">competitors may</font> have greater financial, research and     <font color="blue">development</font>, <font color="blue">manufacturing</font> and <font color="blue">marketing resources than</font> Respironics</td>
    </tr>
    <tr>
      <td>The     <font color="blue">consolidation</font>  by  the  Company’s  <font color="blue">competitors could</font> result in greater     <font color="blue">competition</font></td>
    </tr>
    <tr>
      <td><font color="blue">Increased </font><font color="blue">competition</font> could lead to <font color="blue">greater increases</font> in     pricing  pressure</td>
    </tr>
    <tr>
      <td>If <font color="blue">innovative new products cannot</font> be developed, the     Company may not be able to maintain <font color="blue">competitive pricing</font> and market share</td>
    </tr>
    <tr>
      <td>The decline in the <font color="blue">availability</font> of, or the increase in cost of <font color="blue">raw materials</font>     <font color="blue">could increase</font> the Company’s costs of producing its products or limit the     Company’s ability to <font color="blue">meet sales demand</font></td>
    </tr>
    <tr>
      <td>The  <font color="blue">Company  </font><font color="blue">generally</font> performs all <font color="blue">major assembly</font> work on all of its     products</td>
    </tr>
    <tr>
      <td>It <font color="blue">manufacture</font>s many of the <font color="blue">plastic <font color="blue">components</font></font> for its <font color="blue">face mask</font>     products  and  <font color="blue">uses subcontractors</font> to <font color="blue">supply certain</font> other <font color="blue">components</font>,     including printed circuit boards, motor / <font color="blue">blower assemblies</font>, and plastics</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>purchases the component parts for its <font color="blue">major products from</font> a     number  of <font color="blue"><font color="blue">different</font> suppliers</font></td>
    </tr>
    <tr>
      <td>Where <font color="blue">appropriate</font>, <font color="blue">the Company </font>employs     <font color="blue">contracts with</font> its suppliers, both domestically and <font color="blue">internationally</font></td>
    </tr>
    <tr>
      <td>The     Company believes that its <font color="blue">relationships with</font> its suppliers are satisfactory     and that <font color="blue">alternative</font> sources of supply are available</td>
    </tr>
    <tr>
      <td>The <font color="blue">raw materials</font> used     in  the Company’s <font color="blue">components</font> have <font color="blue">historically been readily available</font></td>
    </tr>
    <tr>
      <td>However, loss of a <font color="blue">key supplier</font> or access to certain <font color="blue">raw materials</font> could     have a material <font color="blue">adverse impact on</font> the Company</td>
    </tr>
    <tr>
      <td>From time-to-time, the prices and <font color="blue">availability</font> of these <font color="blue">raw materials</font> may     <font color="blue">fluctuate due</font> to global market demands, which could impair the Company’s     ability to <font color="blue">procure <font color="blue">necessary</font> materials</font>, or <font color="blue">could increase</font> the cost of such     materials</td>
    </tr>
    <tr>
      <td><font color="blue">Inflationary </font>and other increases in costs of these <font color="blue">raw materials</font>     may occur from time-to-time</td>
    </tr>
    <tr>
      <td>In addition, freight costs <font color="blue">associated with</font>     shipping and receiving product are <font color="blue">impacted by fluctuations</font> in the cost of     oil and gas</td>
    </tr>
    <tr>
      <td>A reduction in the supply or an increase in the cost of those     <font color="blue">raw materials</font> could impact the Company’s ability to <font color="blue">manufacture</font> its products     and <font color="blue">could increase</font> the cost of production</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>is subject to substantial domestic and <font color="blue">international <font color="blue">government</font></font>     regulation,  including  <font color="blue"><font color="blue">regulatory</font> quality standards applicable</font> to its     <font color="blue">manufacturing</font> and <font color="blue">quality processes</font></td>
    </tr>
    <tr>
      <td>Failure by <font color="blue">the Company </font>to comply with     these standards could have an adverse effect on the Company’s business,     <font color="blue">financial condition</font>, or results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The FDA regulates the approval, <font color="blue">manufacturing</font>, and sales and marketing of     many of the Company’s products in the <font color="blue">US Significant </font><font color="blue"><font color="blue">government</font> regulation</font>     also exists in Canada, Japan, Europe, and other countries in which the     Company conducts business</td>
    </tr>
    <tr>
      <td>As a device <font color="blue">manufacture</font>r, <font color="blue">the Company </font>is required     to <font color="blue">register with</font> the FDA and is subject to periodic inspection by <font color="blue">the FDA     </font>for                                           18     ______________________________________________________________________    [44]Table of Contents       <font color="blue">compliance with</font> the FDA’s Quality System Regulation (“QSR”) <font color="blue">requirements</font>,     which  require  <font color="blue">manufacture</font>rs  of <font color="blue">medical devices</font> to adhere to certain     <font color="blue">regulations</font>,  including  testing,  quality  control  and <font color="blue">documentation</font>     procedures</td>
    </tr>
    <tr>
      <td>In addition, the federal <font color="blue">Medical Device Reporting </font><font color="blue">regulations</font>     require <font color="blue">the Company </font>to provide information <font color="blue">to the FDA </font><font color="blue">whenever there</font> is     evidence  that  <font color="blue">reasonably</font>  suggests  that a device may have caused or     contributed to a death or <font color="blue">serious injury</font> or, if a <font color="blue">malfunction</font> were to occur,     could cause or contribute to a death or <font color="blue">serious injury</font></td>
    </tr>
    <tr>
      <td><font color="blue">Compliance </font>with     applicable <font color="blue">regulatory</font> <font color="blue">requirements</font> is subject to <font color="blue">continual review</font> and is     <font color="blue">rigorously</font>  monitored  <font color="blue">through periodic inspections by</font> the FDA In the     European  Community,  the  Company is required to maintain certain ISO     <font color="blue">certifications</font> in order to sell its products and <font color="blue">must undergo periodic</font>     <font color="blue">inspections by notified bodies</font> to obtain and maintain these <font color="blue">certifications</font></td>
    </tr>
    <tr>
      <td><font color="blue">Failure  </font>to  comply  with current <font color="blue"><font color="blue">government</font>al</font> <font color="blue">regulations</font> and quality     assurance  <font color="blue">guidelines</font> could lead to temporary <font color="blue">manufacturing</font> shutdowns,     <font color="blue">product recalls</font> or related field actions, product shortages or delays in     product <font color="blue">manufacturing</font></td>
    </tr>
    <tr>
      <td><font color="blue">Efficacy </font>or safety concerns, an increase in trends of     adverse events in the marketplace, and/or <font color="blue">manufacturing</font> quality issues with     respect to the Company’s <font color="blue">products could lead</font> to <font color="blue">product recalls</font> or related     field actions, withdrawals, and/or declining sales</td>
    </tr>
    <tr>
      <td>From time-to-time <font color="blue">the Company </font>is required to conduct <font color="blue">product recalls</font> and/or     field  <font color="blue">actions <font color="blue">associated with</font> certain</font> of its products</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>is     <font color="blue">currently conducting certain recalls</font> and is <font color="blue">investigating certain customer</font>     product  <font color="blue">complaints</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>has accrued for the anticipated costs     <font color="blue">associated with</font> these <font color="blue">product matters</font> in its <font color="blue"><font color="blue">consolidated balance</font> sheets as</font>     of June 30, 2006 and 2005</td>
    </tr>
    <tr>
      <td>There can be no assurance these accruals are     adequate to cover the <font color="blue">actual costs incurred</font> related to these items</td>
    </tr>
    <tr>
      <td>The pricing, sales and <font color="blue">marketing programs</font> and <font color="blue">arrangements</font>, and related     business  practices of the industry are <font color="blue">under increasing scrutiny from</font>     federal   and   state  <font color="blue">regulatory</font>,  <font color="blue">investigative</font>,  <font color="blue">prosecutorial</font>  and     <font color="blue"><font color="blue">administrative</font> entities</font></td>
    </tr>
    <tr>
      <td>These entities include the <font color="blue">Department of Justice     </font>and its US Attorney’s Offices, the Office of Inspector General of the     <font color="blue">Department  </font>of  Health  and Human Services, the FDA, the Federal Trade     Commission  and  various  state <font color="blue">Attorneys General </font>offices</td>
    </tr>
    <tr>
      <td>Many of the     <font color="blue">healthcare laws under which certain</font> of these <font color="blue"><font color="blue">government</font>al</font> entities operate,     including the federal and state anti-kickback statutes and statutory and     <font color="blue">common law false</font> claims laws, have <font color="blue">been construed broadly by</font> the courts and     permit the <font color="blue"><font color="blue">government</font> entities</font> to <font color="blue">exercise <font color="blue">significant</font> discretion</font></td>
    </tr>
    <tr>
      <td>In the     event that any of those <font color="blue"><font color="blue">government</font>al</font> entities believes that wrongdoing has     occurred, one or more of <font color="blue">them could institute civil</font> or <font color="blue">criminal proceedings</font>,     which, if instituted and resolved unfavorably, could subject <font color="blue">the Company </font>to     substantial fines, penalties and injunctive or <font color="blue">administrative</font> remedies,     including exclusion from <font color="blue">government</font> <font color="blue">reimbursement</font> programs</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>also     cannot  predict  whether  any <font color="blue">investigations will affect</font> its marketing     practices or sales</td>
    </tr>
    <tr>
      <td>Any such result could have a material <font color="blue">adverse impact on</font>     the Company’s results of <font color="blue">operations</font>, <font color="blue">cash flows</font>, <font color="blue">financial condition</font>, or its     business</td>
    </tr>
    <tr>
      <td>Sales may decline if the Company’s customers do not receive <font color="blue">adequate levels</font>     of <font color="blue">reimbursement</font> from third-party payors for the Company’s products and if     certain  types of <font color="blue">healthcare programs</font> are adopted in the Company’s key     markets</td>
    </tr>
    <tr>
      <td>In the United States, healthcare providers that purchase the Company’s     products <font color="blue">generally</font> rely on payments from third-party payors (principally     federal Medicare and private health insurance plans) to cover all or a     portion of the cost of the Company’s products</td>
    </tr>
    <tr>
      <td>In the event that third-party     payors <font color="blue">deny coverage</font> or reduce their current levels of <font color="blue">reimbursement</font>, the     Company may experience increased selling price pressure and/or weakened     demand for its products</td>
    </tr>
    <tr>
      <td>Further, third-party payors are continuing to     <font color="blue">carefully review</font> their <font color="blue">coverage policies with respect</font> to existing and new     therapies and can, without notice, <font color="blue">deny coverage</font> for <font color="blue">treatments</font> that may     include the use of the Company’s products</td>
    </tr>
    <tr>
      <td>Outside  the  US,  <font color="blue">reimbursement</font>  systems  vary  <font color="blue"><font color="blue">significant</font>ly</font>  from     country-to-country</td>
    </tr>
    <tr>
      <td>In the majority of the <font color="blue">international markets</font> in which     the Company’s products are sold, <font color="blue">government</font>-managed healthcare systems     mandate  the  <font color="blue">reimbursement</font>  rates and methods for <font color="blue">medical devices</font> and     procedures</td>
    </tr>
    <tr>
      <td>If <font color="blue">adequate levels</font> of <font color="blue">reimbursement</font> from third-party payors     outside of the US are not obtained, <font color="blue">international sales</font> of the Company’s     <font color="blue">products may decline</font></td>
    </tr>
    <tr>
      <td>Many <font color="blue">foreign markets</font>, including Canada, and some     European  and Asian countries, have tightened <font color="blue">reimbursement</font> rates</td>
    </tr>
    <tr>
      <td>The     ability  of  the  <font color="blue">Company  </font>to continue to sell certain of its products     profitably  in  these  markets  may diminish if the <font color="blue">government</font>-managed     healthcare systems continue to reduce <font color="blue">reimbursement</font> rates</td>
    </tr>
    <tr>
      <td>19     ______________________________________________________________________    [45]Table of Contents       A natural or man-made disaster could have a material adverse effect on the     Company’s business</td>
    </tr>
    <tr>
      <td>The  <font color="blue">Company  </font>has  <font color="blue">approximately</font>  ten <font color="blue">manufacturing</font> <font color="blue">operations</font> located     <font color="blue">throughout</font>  the world</td>
    </tr>
    <tr>
      <td>However, a <font color="blue">significant</font> portion of the Company’s     products are produced at its <font color="blue">facility</font> in Murrysville, Pennsylvania</td>
    </tr>
    <tr>
      <td>In the     event that this <font color="blue">facility</font> or any other <font color="blue">significant</font> <font color="blue">facility</font> were severely     damaged or <font color="blue">destroyed as</font> a result of a natural or man-made disaster, the     Company would be forced to shift production to its other <font color="blue">facilities</font> and/or     rely on third-party <font color="blue">manufacture</font>rs</td>
    </tr>
    <tr>
      <td>Such an event could have a material     adverse  effect  on  the Company’s business, results of <font color="blue">operations</font> and     <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>also operates a substantial amount of its business <font color="blue">transactions</font>     on an <font color="blue">integrated enterprise resource</font> planning system</td>
    </tr>
    <tr>
      <td>Failure by the <font color="blue"><font color="blue">Company  </font>   </font>to protect its systems from a cyber attack or other <font color="blue">security breach could</font>     have a material <font color="blue">adverse impact on</font> the Company</td>
    </tr>
    <tr>
      <td>COMPANY RISKS        The Company’s <font color="blue">future <font color="blue">profitability</font> <font color="blue">depends on</font></font> the success of the Company’s     <font color="blue">principal product lines</font></td>
    </tr>
    <tr>
      <td>Sales of the Company’s <font color="blue">sleep <font color="blue">apnea products</font> accounted</font> for <font color="blue">approximately</font> 54prca     of the Company’s net sales for the year ended June 30, 2006</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>    expects  sales  of  sleep  <font color="blue">apnea products</font> to continue to account for a     <font color="blue">significant</font> portion of the Company’s <font color="blue">aggregate sales</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">event <font color="blue">adversely</font></font>     affecting the sale of sleep <font color="blue">apnea products</font> may, as a result, <font color="blue">adversely</font>     affect  the  Company’s  business,  results of <font color="blue">operations</font> and financial     condition</td>
    </tr>
    <tr>
      <td>The success of <font color="blue">the Company </font><font color="blue">depends on</font> its ability to <font color="blue">effectively market</font> to     <font color="blue">home healthcare providers</font> and <font color="blue">sleep <font color="blue">laboratories</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font><font color="blue">markets certain products primarily</font> to <font color="blue">homecare providers</font> and to     <font color="blue">sleep clinics</font> that diagnose OSA and other <font color="blue">sleep disorders</font></td>
    </tr>
    <tr>
      <td>The role of     homecare  providers  and  sleep  <font color="blue">laboratories</font>  is  <font color="blue">significant</font>  in the     <font color="blue">determination</font> of the brand of product a <font color="blue">patient will use</font></td>
    </tr>
    <tr>
      <td>The Company’s     success  depends  on its ability to <font color="blue">effectively market</font> its products to     <font color="blue">homecare providers</font> and <font color="blue">sleep <font color="blue">laboratories</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>markets to <font color="blue">approximately</font> 3cmam500 US <font color="blue">sleep <font color="blue">laboratories</font></font> and     <font color="blue">approximately</font> 6cmam500 <font color="blue">homecare providers</font>, most of which use, sell or recommend     multiple  brands  of  products</td>
    </tr>
    <tr>
      <td><font color="blue">Declining </font><font color="blue"><font color="blue">government</font>al</font> and third-party     <font color="blue">reimbursement</font> amounts have caused pricing pressure on <font color="blue">homecare providers</font></td>
    </tr>
    <tr>
      <td>Due to this, <font color="blue">homecare providers</font> may require price <font color="blue">discounts</font> and longer     periods of time to pay for products purchased</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font><font color="blue">cannot assure</font>     that <font color="blue">sleep physicians will continue</font> to prescribe Respironics’ products, or     that <font color="blue">homecare providers</font> or <font color="blue">patients will</font> not <font color="blue">substitute competing products</font>     when a <font color="blue">prescription specifying</font> the Company’s products has <font color="blue">been written</font></td>
    </tr>
    <tr>
      <td><font color="blue">Marketing </font><font color="blue">activities targeted toward</font> the <font color="blue">population with</font> a <font color="blue">predisposition</font> to     sleep-disordered breathing, as well as primary care physicians and various     <font color="blue">medical specialists</font>’ are ongoing</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font><font color="blue">cannot assure</font> that these     <font color="blue">marketing efforts will</font> be successful in <font color="blue">increasing awareness</font> of OSA or sales     <font color="blue">of Company </font>products</td>
    </tr>
    <tr>
      <td>The  <font color="blue">inability</font> to <font color="blue">support continued growth could <font color="blue">negatively impact</font></font> the     Company</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>has experienced substantial growth</td>
    </tr>
    <tr>
      <td>The effective <font color="blue">management</font> of     growth depends upon, among other things, the ability to monitor and improve     <font color="blue">manufacturing</font>  systems, information <font color="blue">technology</font>, quality and <font color="blue">regulatory</font>     <font color="blue">compliance systems</font>, and financial and <font color="blue">management</font> reporting systems</td>
    </tr>
    <tr>
      <td>The     failure to attract and retain <font color="blue">qualified employees</font>, the failure to manage     costs,  or  the  <font color="blue">inability</font>  to <font color="blue">support current</font> and <font color="blue">future growth could</font>     <font color="blue">negatively impact</font> the Company</td>
    </tr>
    <tr>
      <td>The Company’s revenues are subject to risks arising <font color="blue">from currency exchange</font>     rate fluctuations, which could <font color="blue">adversely</font> affect the Company’s results of     <font color="blue">operations</font> or <font color="blue">financial position</font></td>
    </tr>
    <tr>
      <td>During fiscal year 2006, sales of the Company’s products in <font color="blue">foreign markets</font>     <font color="blue">approximated</font>  dlra178cmam814cmam000  or  17prca  of  the Company’s <font color="blue">total revenues</font></td>
    </tr>
    <tr>
      <td>Accordingly,  the US <font color="blue">dollar value</font> of the Company’s foreign-generated     revenues varies with currency exchange rate fluctuations</td>
    </tr>
    <tr>
      <td>Currency exchange     rates are subject to <font color="blue">fluctuation due</font> to, among other things, changes in     local, regional, or global economic <font color="blue">conditions</font>, the imposition of currency     <font color="blue">exchange restrictions</font>, and unexpected changes in <font color="blue">regulatory</font> or taxation     <font color="blue">environments</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">local country currency</font> of the Company’s <font color="blue">subsidiaries</font>     outside the US is the <font color="blue">predominant currency used by</font> the <font color="blue">subsidiaries</font> to     transact business</td>
    </tr>
    <tr>
      <td>Through its international <font color="blue">operations</font>, the company is     exposed to <font color="blue">foreign currency fluctuations</font>, and changes in <font color="blue">exchange rates</font> can     have a <font color="blue">significant</font> impact on the Company’s results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>20     ______________________________________________________________________    [46]Table of Contents       <font color="blue">The Company </font>is subject to <font color="blue">certain risks inherent</font> in managing a global and     <font color="blue"><font color="blue">decentralized</font> <font color="blue">organization</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>has <font color="blue">significant</font> international <font color="blue">operations</font> and operates under a     <font color="blue"><font color="blue">decentralized</font> operational structure</font></td>
    </tr>
    <tr>
      <td>Certain risks are inherent in operating     and <font color="blue">selling products</font> in a global and <font color="blue"><font color="blue">decentralized</font> <font color="blue">organization</font></font>, including:         •   <font color="blue">Difficulties </font>in enforcing <font color="blue">agreements</font> and collecting <font color="blue">receivables</font> through     certain foreign legal systems;         •   Foreign customers who may have <font color="blue">longer payment cycles than customers</font> in     the US;         •   Tax rates in <font color="blue">certain foreign countries</font> that may exceed those in the     US, and foreign earnings that may be subject to withholding <font color="blue">requirements</font>;         •   The imposition of tariffs, exchange controls or other <font color="blue">trade restrictions</font>     including <font color="blue">transfer pricing restrictions</font> when products produced in one     country are sold to an <font color="blue">affiliated</font> entity in another country;         •   General economic and political <font color="blue">conditions</font> in countries where the <font color="blue"><font color="blue">Company  </font>   </font>operates or where end users of the Company’s <font color="blue">products reside</font>;         •   <font color="blue">Difficulties </font>in enforcing <font color="blue">intellectual</font> property rights and weaker     <font color="blue">intellectual</font> property rights protection in some countries;         •   Required <font color="blue">compliance with</font> a variety of <font color="blue">foreign laws</font> and <font color="blue">regulations</font>; and;         •   Other <font color="blue">difficult</font>ies <font color="blue">associated with</font> managing a <font color="blue">decentralized</font>     <font color="blue">organization</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">inability</font> to <font color="blue">effectively market</font> the Company’s <font color="blue">products outside</font> the US     could <font color="blue">adversely</font> impact <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td><font color="blue">Approximately </font>30prca of the Company’s revenues are <font color="blue">generated outside</font> the US,     in <font color="blue">approximately</font> 131 <font color="blue">different</font> countries</td>
    </tr>
    <tr>
      <td>Many of these countries have     unique <font color="blue">regulatory</font>, medical, and business <font color="blue">environments</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">inability</font> to     <font color="blue">effectively market</font> the Company’s <font color="blue">products outside</font> the US could have an     adverse  impact  on  the Company’s business, results of <font color="blue">operations</font> and     <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>The Company’s <font color="blue">acquisition</font> and <font color="blue">strategic investment activity may</font> not be     successful</td>
    </tr>
    <tr>
      <td>As  a part of the Company’s <font color="blue">growth strategy</font>, <font color="blue">the Company </font>seeks to make     strategic  investments  and  <font color="blue">acquisition</font>s  of companies, products, and     <font color="blue">technologies</font> to expand its presence in the sleep and <font color="blue">respiratory markets</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>may not be able to <font color="blue">successfully manage</font> and <font color="blue">integrate future</font>     <font color="blue">acquisition</font>s and <font color="blue">strategic investments</font></td>
    </tr>
    <tr>
      <td>There are <font color="blue">no assurances</font> that any     <font color="blue">acquisition</font> or <font color="blue">investment opportunities will</font> arise or if they do, that they     will  be  consummated, or that any needed <font color="blue">additional financing will</font> be     <font color="blue">available on</font> satisfactory terms when required</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">acquisition</font>s and     strategic  investments  <font color="blue">involve risks</font> that the <font color="blue">businesses</font>, products or     <font color="blue">technology</font> acquired will not perform in <font color="blue">accordance with expectations</font>, that     business  judgments  <font color="blue">concerning</font> the value, strengths and <font color="blue">weaknesses</font> of     <font color="blue">businesses</font> or <font color="blue">technology</font> acquired will prove incorrect, that the acquired     <font color="blue">businesses</font> or <font color="blue">technology</font> may not be <font color="blue">integrated successfully</font>, and that the     <font color="blue">acquisition</font>s may strain <font color="blue">management</font> resources</td>
    </tr>
    <tr>
      <td>The  <font color="blue">integration</font>  of  <font color="blue">operations</font>  of acquired companies, including the     <font color="blue">consolidation</font>  of  systems,  procedures, personnel and <font color="blue">facilities</font>, the     <font color="blue">relocation</font>  of staff, and the <font color="blue">achievement</font> of anticipated <font color="blue">cost savings</font>,     economies of scale and other business efficiencies, presents <font color="blue">significant</font>     challenges, particularly if several <font color="blue">acquisition</font>s occur within a short period     of time</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>may not be able to <font color="blue">successfully integrate</font> any business,     products, <font color="blue">technologies</font> or personnel that may be acquired in the future, and     the failure to do so could <font color="blue">adversely</font> affect the Company</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>may be <font color="blue">adversely</font> affected by the outcome of <font color="blue">legal proceedings</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>may be party to various <font color="blue">legal proceedings</font> which could result in     substantial costs and <font color="blue">could harm</font> the Company’s on-going <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The     results of <font color="blue">legal proceedings</font> are <font color="blue">difficult</font> to predict</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>cannot     <font color="blue">provide assurance</font> that an action or proceeding will not be <font color="blue">commenced against</font>     it, or that <font color="blue">the Company </font><font color="blue">will prevail</font> in any <font color="blue">such action</font> or proceeding</td>
    </tr>
    <tr>
      <td>An     <font color="blue">unfavorable resolution</font> of any <font color="blue">legal action</font> or <font color="blue">proceeding could materially</font>     and  <font color="blue">adversely</font>  affect  the Company’s business, results of <font color="blue">operations</font>,     liquidity  or  financial  condition</td>
    </tr>
    <tr>
      <td>The  Company does accrue for the     anticipated costs <font color="blue">associated with</font> legal matters in its <font color="blue">consolidated balance</font>     sheets  as  of June 30, 2006 and 2005</td>
    </tr>
    <tr>
      <td>There can be no assurance these     accruals are adequate to cover the <font color="blue">actual costs incurred</font> related to these     matters</td>
    </tr>
    <tr>
      <td>The Company’s <font color="blue">intellectual</font> property rights may expire, or they may not     <font color="blue">sufficiently protect</font> its products, or the Company’s <font color="blue">products may infringe on</font>     the <font color="blue">intellectual</font> property rights of <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>The  <font color="blue">Company  </font>relies  on  a  <font color="blue">combination</font> of patents, trade secrets and     non-disclosure  <font color="blue">agreements</font>  to  protect its <font color="blue">intellectual</font> property</td>
    </tr>
    <tr>
      <td>The     Company’s <font color="blue">success depends</font>, in part, on its ability to obtain and maintain     US and foreign patent protection for its products</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>currently     has a number of <font color="blue">pending patent <font color="blue">applications</font></font></td>
    </tr>
    <tr>
      <td>It is not possible to determine     whether  the  Company will obtain any <font color="blue">patents from</font> these <font color="blue">applications</font></td>
    </tr>
    <tr>
      <td>Additionally,  the  claims  in  <font color="blue">previously</font>  issued  patents or pending     <font color="blue">applications</font> may not provide <font color="blue">the Company </font>with <font color="blue">significant</font> protection against     <font color="blue">competitive products</font> or otherwise be <font color="blue">commercially</font> valuable</td>
    </tr>
    <tr>
      <td>Additionally,     third party patents, patent <font color="blue">applications</font>, and other <font color="blue">intellectual</font> property,     which are not known to the Company, may block or <font color="blue">compete with</font> the Company’s     <font color="blue">existing product lines</font></td>
    </tr>
    <tr>
      <td>21     ______________________________________________________________________    [47]Table of Contents       Litigation may be <font color="blue">necessary</font> to enforce the Company’s patents, to protect     <font color="blue">existing proprietary rights</font>, or to <font color="blue">defend third party infringement</font> claims</td>
    </tr>
    <tr>
      <td>The  defense and <font color="blue">prosecution</font> of patent claims, including these pending     claims, <font color="blue">as well as participation</font> in other inter-party proceedings, can be     expensive and time consuming, even in those instances in which the outcome     is favorable</td>
    </tr>
    <tr>
      <td>If the outcome of any <font color="blue">litigation</font> or proceeding were adverse,     <font color="blue">the Company </font>could be subject to <font color="blue">significant</font> liabilities to <font color="blue">third parties</font>,     could be required to obtain licenses from <font color="blue">third parties</font>, may be forced to     redesign or rename its products, or could be required to <font color="blue">cease sales</font> of the     <font color="blue">affected products</font></td>
    </tr>
    <tr>
      <td>Additionally, the laws regarding the <font color="blue">enforceability</font> of     patents vary by country; therefore, any patent issues faced by the <font color="blue"><font color="blue">Company  </font>   </font>may not be <font color="blue">uniformly resolved</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>is exposed to certain credit risks, resulting <font color="blue">primarily from</font>     <font color="blue">customer sales</font></td>
    </tr>
    <tr>
      <td><font color="blue">Substantially  </font>all  of the Company’s <font color="blue">receivables</font> are <font color="blue">due from homecare</font>     providers, distributors, hospitals, and <font color="blue">independent leasing companies</font></td>
    </tr>
    <tr>
      <td>The     Company’s customers are located <font color="blue">throughout</font> the US and around the world</td>
    </tr>
    <tr>
      <td>A     <font color="blue">significant</font>  portion  of  <font color="blue">products sold</font> to providers, distributors and     hospitals,  both  foreign  and  domestic, is <font color="blue">ultimately funded through</font>     <font color="blue">government</font> <font color="blue">reimbursement</font> programs or <font color="blue">through private insurance programs</font></td>
    </tr>
    <tr>
      <td>As     a consequence, changes in these programs can have an <font color="blue">adverse impact on</font> the     liquidity and <font color="blue">profitability</font> of the Company’s <font color="blue">customer base</font></td>
    </tr>
    <tr>
      <td>In addition,     because  a  <font color="blue">concentration</font> of market share exists in the sleep and home     <font color="blue">respiratory product industry</font> in the US <font color="blue">among national</font> and large regional     <font color="blue">homecare providers</font>, <font color="blue">the Company </font>experiences a comparable <font color="blue">concentration</font> of     credit risk with these customers</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>records an estimated allowance for <font color="blue">uncollectible amounts based</font>     <font color="blue">primarily on</font> the Company’s <font color="blue">evaluation</font> of the payment pattern, financial     condition,  <font color="blue">cash flows</font>, and credit history of its <font color="blue">customers as well as</font>     <font color="blue">current industry</font> and economic <font color="blue">conditions</font></td>
    </tr>
    <tr>
      <td>Respironics’s <font color="blue">inability</font> to collect     on its trade accounts receivable from major customers could substantially     reduce  the Company’s income and have a material adverse effect on its     <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
  </tbody>
</table>